BB Biotech AG : Q2 in decline after a good start to the year
>Net loss of CHF 87m in Q2 - BB Biotech reported its Q2 2024 figures this morning. Over the period, the share price has shed -12% in CHF and -11.3% in euros. The performance of its portfolio, while it is better quality compared to the share price, is in negative territory at -3.5% in CHF, -2.6% in € and -3.3% in USD, underperforming the benchmark Nasdaq Biotech Index (+2.8% in $ over the period). This results in a net loss of -CHF 87m vs -CHF 13m in the same period fo...Co.'s principal activity is to invest in biotechnology companies globally. The investments are held through its wholly-owned subsidiaries: Biotech Focus N.V., Biotech Invest N.V., Biotech Target N.V., and Biotech Growth N.V., all of which are located in Curacao. Co. acquires holdings in companies in the biotechnology growth market. The focus of the holdings is on quoted companies that are concentrating on the development and marketing of innovative medicines. For the selection of holdings, Co. relies on fundamental analysis by physicians and molecular biologists.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.